Eyevensys announced the expansion of its executive team with the addition of Ronald R. Buggage, MD, as its Chief Medical Officer. Dr. Buggage brings more than 14 years experience from both large pharma and biotech companies having worked in senior development positions in the US and Europe. Dr. Buggage will drive the company's drug development strategy, overseeing clinical development programs for a broad range of ophthalmic indications based Eyevensys' non-viral gene therapy EyeCET platform.
Dr. Buggage was most recently Division Medical Officer at Sanofi's ophthalmology unit, responsible for the leadership and coordination of medical and scientific activities for its ophthalmology portfolio including development programs for ocular gene therapy. He also served as Chief Scientific Officer of Novagali Pharma, where he was responsible for the global clinical and regulatory strategy. Novagali Pharma was successfully acquired by Santen. Prior to moving to France, Dr. Buggage held various positions of increasing clinical development responsibility at Novartis and Pfizer. Dr. Buggage obtained his MD at UCLA School of Medicine, specializing in ophthalmology at Emory, and completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health (NIH).
"We are delighted to add such an experienced and high-calibre individual to our executive team," Raffy Kazandjian, CEO of Eyevensys, said in a company news release. "Ronald's unique combination of regulatory, medical, and drug development expertise in the ophthalmic space, including uveitis, will be a major asset as Eyevensys advances its high potential pipeline. This includes our lead product EYS606 for which the first in human phase I/II clinical trial was recently initiated in France."
"I am particularly thrilled to join Eyevensys at such a pivotal time," Dr. Buggage said in the news release. "Its proprietary EyeCET platform offers an innovative approach to sustained intraocular drug delivery which combined with the non-viral delivery of the plasmids provides a convenient alternative to current biologics used to treat ophthalmic diseases. I believe that with EyeCET, Eyevensys has the potential to build an exciting, high value pipeline of new ocular therapies."
Eyevensys is a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases, according to the company.